We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

RERE:NYSEATRenew Inc. Analysis

Data as of 2026-09-02 - not real-time

$4.14

Latest Price

9/10Risk

Risk Level: High

Executive Summary

The moving-average structure behind ATRenew Inc. is neutral at $4.14, with no clear ordering between short and long averages. It has gained 5.1% over the past 30 days. RSI sits at 47.9, which reads as neutral, and MACD momentum is bearish. The recent range runs from support at $3.86 up to resistance at $4.71.
Multiples put this in undervalued territory at a P/E of 13.8. Consensus targets land 59.6% above where the shares trade now. Revenue is growing at 32.4% on a 2.0% profit margin. The 2.42% dividend yield looks covered by current payout levels.
Risk comes out at 9 of a possible 10, a high reading. With 30-day volatility of 53.5%, a beta of 1.39 and a maximum drawdown of 42.9%, position sizing matters more than entry timing here. The wider market backdrop reads extreme greed at 92 on the fear-greed composite.
The horizons line up on hold — conviction 2 out of 10.

Top Market Events

Updated Aug 6, 2026 0 SHANGHAI, Aug. 6, 2026 /PRNewswire/ -- ATRenew Inc. "ATRenew" or the "Company" NYSE: RERE , a...ATRenew Inc. "ATRenew" or the "Company" NYSE: RERE , a pioneer in technology-driven recycling and trade-in solutions...Benzinga.com13dATRenew Earnings & ForecastsATRenew RERE last issued guidance on August 20, 2026 for Q3 2026. The...

Market Outlook

Short Term

< 1 year
Neutral
Model confidence: 1/10

Key Factors

  • Trading below the 200-day average of 4.82
  • MACD momentum is negative
  • 30-day price change of +5.1%

Medium Term

1–3 years
Neutral
Model confidence: 1/10

Key Factors

  • Trading below the 200-day average of 4.82
  • Analyst targets imply +59.6% versus the current price
  • 30-day volatility of 53.5%

Long Term

> 3 years
Neutral
Model confidence: 2/10

Key Factors

  • Analyst targets imply +59.6% versus the current price
  • Revenue growth of +32.4%
  • P/E ratio of 13.8

Key Metrics & Analysis

Financial Health

Revenue Growth32.40%
Profit Margin2.01%
P/E Ratio13.8
ROE12.35%
ROA7.13%
Debt/Equity13.15
P/B Ratio1.7

Technical Analysis

TrendNeutral
RSI47.9
Support$3.86
Resistance$4.71
MA 20$4.30
MA 50$4.11
MA 200$4.82
MACDBearish
VolumeIncreasing
Fear & Greed Index92.02

Valuation

Target Price$6.61
Upside/Downside59.55%
GradeUndervalued
TypeBlend
Dividend Yield2.42%

Risk Assessment

Beta1.39
Volatility53.48%
Sector RiskHigh
Reg. RiskLow
Geo RiskHigh
Currency RiskLow
Liquidity RiskMedium

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.